{"id":2380,"date":"2025-01-10T11:32:46","date_gmt":"2025-01-10T08:32:46","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2380"},"modified":"2025-03-27T16:49:38","modified_gmt":"2025-03-27T13:49:38","slug":"nippon-shinyaku-releases-first-clinical-trial-first-in-human-of-brogidirsen-ns-089-ncnp-02-for-the-treatment-of-duchenne","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/nippon-shinyaku-releases-first-clinical-trial-first-in-human-of-brogidirsen-ns-089-ncnp-02-for-the-treatment-of-duchenne\/","title":{"rendered":"Nippon Shinyaku publica el primer ensayo cl\u00ednico (el primero en humanos) de Brogidirsen NS-089\/NCNP-02 para el tratamiento de la distrofia muscular de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">El Centro Nacional de Neurolog\u00eda y Psiquiatr\u00eda anunci\u00f3 la publicaci\u00f3n de un art\u00edculo de investigaci\u00f3n en Cell Reports Medicine que detalla los resultados de un ensayo iniciado por investigadores para NS-089\/NCNP-02, conocido como \u201cbrogidirsen\u201d. Este tratamiento innovador para la distrofia muscular de Duchenne (DMD), desarrollado en conjunto con Nippon Shinyaku Co., Ltd., representa un avance significativo en la terapia de omisi\u00f3n del ex\u00f3n 44.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Tabla de contenido<\/h2><nav><ul><li><a href=\"#key-findings-from-brogidirsen-include\">Resultados del ensayo cl\u00ednico Brogidirsen<\/a><\/li><li><a href=\"#what-is-brogidirsen\">\u00bfQu\u00e9 es Brogidirsen?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"key-findings-from-brogidirsen-include\">Resultados del ensayo cl\u00ednico Brogidirsen<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Brogidirsen muestra una restauraci\u00f3n de la distrofina dependiente de la dosis en ensayos con pacientes con DMD.<\/li>\n\n\n\n<li>El brogidirsen en dosis altas alcanz\u00f3 24,47% del nivel normal de distrofina en la cohorte DMD.<\/li>\n\n\n\n<li>El ensayo demostr\u00f3 beneficios terap\u00e9uticos con una funci\u00f3n motora estable o mejorada y un perfil de seguridad favorable sin eventos adversos graves.<\/li>\n\n\n\n<li>Se identificaron biomarcadores s\u00e9ricos para DMD, incluidos PADI2, TTN, MYOM2 y MYLPF.<\/li>\n\n\n\n<li>Brogidirsen mostr\u00f3 una alta eficacia en c\u00e9lulas derivadas de orina de DMD, lo que respalda los ensayos en humanos.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-brogidirsen\">\u00bfQu\u00e9 es Brogidirsen?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Brogidirsen (NS-089\/NCNP-02) es un f\u00e1rmaco de \u00e1cido nucleico codescubierto por Nippon Shinyaku y NCNP, y se espera que sea un f\u00e1rmaco terap\u00e9utico para pacientes con DMD con mutaciones del gen de la distrofina susceptibles de omisi\u00f3n del ex\u00f3n 44.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>M\u00e1s informaci\u00f3n:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/es\/upcoming-exon-44-skipping-therapies-for-dmd\/\" data-type=\"post\" data-id=\"2811\">Pr\u00f3ximas terapias de omisi\u00f3n del ex\u00f3n 44 para el tratamiento de la distrofia muscular de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The National Center of Neurology and Psychiatry is announced the publication of a research paper in Cell Reports Medicine detailing the results of an investigator-initiated trial for NS-089\/NCNP-02, known as &#8220;brogidirsen.&#8221; This innovative treatment for Duchenne muscular dystrophy (DMD), jointly developed with Nippon Shinyaku Co., Ltd., represents a significant advancement in exon 44 skipping therapy. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[138,137,141,127,77,142,136,139,140],"class_list":["post-2380","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-brogidirsen","tag-clinical-trial","tag-exon-44","tag-exon-44-skipping","tag-exon-skipping","tag-japan","tag-nippon-shinyaku","tag-ns-089","tag-ns-089-ncnp-02"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=2380"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2380\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/2383"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=2380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=2380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=2380"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}